X

Astrazeneca Pharma India Ltd. Stock Analysis

Mid Cap
Evaluated by 1332 users | BSE: 506820 | NSE: ASTRAZEN |
Pharmaceuticals & Drugs

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection....

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd. has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 39.66%10.55%-65.39%-9.59%-13.04%3.56%10.77%11.13%19.7%21.98%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 475531390474517564544571728832
Y-o-Y Gr. Rt.-11.8%-26.5%21.4%9.1%9%-3.6%5%27.6%14.2%
Adjusted EPS (Rs.) 20.577.78-37.8-5.21-8.42.188.1610.4521.5828.93
Y-o-Y Gr. Rt.--62.2%-585.9%NANANA274.3%28.1%106.5%34.1%
Book Value per Share (Rs.) 57.575.7139.968.6460.362.4188.4997.94119.48145.14
Adjusted Net Profit 51.419.5-94.5-13-215.520.426.15472.3
Net Op. Cash Flow (Rs. Cr.) 51.638.7-6-0.8-45.75738.18.85587.4
Debt to Cash Flow from Ops 0000000000
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Astrazeneca Pharma India Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 6.4%10%15.2%14.2%
Adjusted EPS 3.9%NA52.5%34.1%
Book Value per Share 10.819.217.921.5
Share Price 15.3% 32.1% 59.8% 71.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 39.6610.55-65.39-9.59-13.043.5610.7711.1319.721.74
Operating Profit Margin (%) 17.525.76-17.51-2.74-2.212.976.898.169.7914.56
Net Profit Margin (%) 10.833.67-24.21-2.75-4.060.973.754.587.418.69
Debt to Equity 0000000000
Working Capital Days 89117171155173167185216177168
Cash Conversion Cycle 50555117111711120-2
Entity Percentage Holding
Promoters 75.00%
Institutions 4.31%
Non-Institutions 20.69%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Astrazeneca Pharma India Ltd. and arrived at the following conclusion:

Past 10 year's financial track record indicates that Astrazeneca Pharma India Ltd. is a below average quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Astrazeneca Pharma India Ltd.'s performance infers:

Astrazeneca Pharma India Ltd. earnings have grown by 0%, whereas share price has appreciated 32.1% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Astrazeneca Pharma India Ltd. share prices over the last 10 years. Here is what we found out:

Astrazeneca Pharma India Ltd. share price has appreciated 14% annually over the past ten years.

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback